Kidney Cancer Weekly

November 24, 2025

Videos

Peer-to-Peer Clinical Conversations

COSMIC-313 Correlative Analysis Links Specific T-Cell Subset to Improved PFS with Immunotherapy - Berkay Simsek

Pedro Barata hosts Berkay Simsek to discuss correlative biomarker analysis from the COSMIC-313 trial examining immune cell populations in patients receiving ipilimumab plus nivolumab for advanced clear cell renal cell carcinoma.

LenCabo Phase II Trial Investigates Lenvatinib-Everolimus vs Cabozantinib in Relapsed Kidney Cancer - Andrew Hahn

Andrew Hahn

Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 checkpoint inhibitors.

Beyond the Abstracts

Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma - Beyond the Abstract

Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

ESMO 2025: Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a Phase II Trial of a Novel RNAseq-based Biomarker

ESMO 2025: First-line Pembrolizumab-based Regimens for Advanced Clear Cell Renal Cell Carcinoma: KEYMAKER-U03 Substudy 03A

ESMO 2025: LenCabo: A Randomized Phase II Multicenter Trial of Lenvatinib plus Everolimus versus Cabozantinib in Patients with Metastatic Clear Cell RCC that Progressed on PD-1 Immune Checkpoint Inhibition

ESMO 2025: Kidney Cancer Discussant: Can we Combine More in Line 1 and Line 2?

ESMO 2025: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant in First-line Advanced RCC: A Kidney Cancer Research Consortium Study

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Neoadjuvant pembrolizumab and tyrosine kinase inhibitor to facilitate imperative partial nephrectomy for renal cell carcinoma.

Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.

Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter study.

Unraveling Smooth Muscle-Rich Renal Cell Carcinoma: Clinical, Oncological, Genetic, and Pathological Insights.

Partial vs. radical nephrectomy in pT3a renal cancer: Cancer-specific mortality according to fat invasion pattern.

Partial nephrectomy Vs. Percutaneous thermal ablation of small renal masses.

Computed tomography guided microwave ablation for the treatment of clinical T1a renal cell carcinoma: a comparison to robot-assisted laparoscopic partial nephrectomy.

Impact of Upstaging From cT2a-b to pT3a on Overall Survival Among Patients With Renal Cell Carcinoma - Beyond the Abstract

The effect of neighborhood deprivation on access to surgical care for pediatric renal tumors.

TFE3-rearranged and TFEB-altered renal cell carcinoma: from classification to real-life. Insights from a national Italian survey.

Utilization of radical nephrectomy for patients with clinical stage T1 renal masses: Evaluation of opportunities for quality improvement.

CONNECT WITH US

Questions or Comments? Email us at

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC